391 related articles for article (PubMed ID: 27988438)
1. Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Hoxha A; Banzato A; Ruffatti A; Pengo V
Autoimmun Rev; 2017 Feb; 16(2):173-178. PubMed ID: 27988438
[TBL] [Abstract][Full Text] [Related]
2. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Favaloro EJ; Mohammed S; Curnow J; Pasalic L
Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
[TBL] [Abstract][Full Text] [Related]
3. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
Reda S; Brügelmann A; Müller J; Oldenburg J; Pötzsch B; Rühl H
Sci Rep; 2020 Jul; 10(1):12221. PubMed ID: 32699227
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
De Kesel PM; Devreese KMJ
J Thromb Haemost; 2020 Aug; 18(8):2003-2017. PubMed ID: 32400112
[TBL] [Abstract][Full Text] [Related]
5. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
6. Lupus-anticoagulant testing at NOAC trough levels.
Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
[TBL] [Abstract][Full Text] [Related]
7. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
[TBL] [Abstract][Full Text] [Related]
8. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
10. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
Tripodi A; Scalambrino E; Chantarangkul V; Paoletti O; Clerici M; Novembrino C; Boscolo-Anzoletti M; Peyvandi F; Testa S
Thromb Res; 2021 Aug; 204():32-39. PubMed ID: 34126321
[TBL] [Abstract][Full Text] [Related]
11. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
12. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.
Arachchillage DR; Mackie IJ; Efthymiou M; Isenberg DA; Machin SJ; Cohen H
J Thromb Haemost; 2015 Jul; 13(7):1264-73. PubMed ID: 25850997
[TBL] [Abstract][Full Text] [Related]
13. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Pratt J; Crispin P
Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
16. Simple method for removing DOACs from plasma samples.
Exner T; Michalopoulos N; Pearce J; Xavier R; Ahuja M
Thromb Res; 2018 Mar; 163():117-122. PubMed ID: 29407622
[TBL] [Abstract][Full Text] [Related]
17. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
18. Measurement and reversal of the direct oral anticoagulants.
Samuelson BT; Cuker A
Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory.
Seheult JN; Meyer MP; Bontempo FA; Chibisov I
Am J Clin Pathol; 2017 Jun; 147(6):632-640. PubMed ID: 28525532
[TBL] [Abstract][Full Text] [Related]
20. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
